Sobi news
Sobi (Swedish Orphan Biovitrum) is a global biopharmaceutical company that develops and commercializes innovative treatments for rare and specialty diseases. Here are some recent news and updates from Sobi:
Recent News:
- Sobi announces positive results from Phase III study of Kineret in pediatric patients with Still's disease: In February 2023, Sobi announced positive results from a Phase III study of Kineret (anakinra) in pediatric patients with Still's disease, a rare and debilitating autoimmune disorder.
- Sobi receives FDA approval for Kineret in Japan: In January 2023, Sobi announced that the Japanese Ministry of Health, Labour and Welfare had approved Kineret for the treatment of Still's disease and other autoimmune disorders.
- Sobi partners with Pfizer to develop gene therapy for rare genetic disorder: In December 2022, Sobi announced a partnership with Pfizer to develop a gene therapy for the rare genetic disorder, Mucopolysaccharidosis Type IIIA (MPS IIIA).
Recent Updates:
- Sobi's pipeline: Focus on rare and specialty diseases: Sobi's pipeline includes several promising therapies for rare and specialty diseases, including Kineret, which is being developed for various autoimmune disorders, and a gene therapy for MPS IIIA.
- Sobi's commercial portfolio: Strong presence in Europe and Japan: Sobi has a strong commercial presence in Europe and Japan, with a portfolio of products that includes Kineret, Elelyso, and others.
- Sobi's commitment to patient advocacy: Sobi is committed to patient advocacy and has established partnerships with patient organizations to support the development of new treatments for rare and specialty diseases.
Please note that this information is subject to change and may not be comprehensive. For the latest news and updates from Sobi, I recommend visiting their official website or following reputable news sources.